Saturday, June 28, 2025
spot_img

Sun Pharma gets DCGI nod for Merck’s anti-Covid pill in India

Date:

Share post:

spot_imgspot_img

New Delhi, Dec 28: Sun Pharmaceutical Industries on Tuesday announced that one of its wholly owned subsidiaries has received emergency use authorisation (EUA) from the Drugs Controller General of India (DCGI) to manufacture and market a generic version of Merck’s anti-Covid pill Molnupiravir in India.

Sun Pharma will launch Molnupiravir under the brand name Molxvir in India, within a week, the company said in a statement.

Amid the ongoing resurgence of new Covid-19 cases in India, an expert panel of the Central Drugs Standard Control Organisation on Tuesday approved Merck’s anti-viral drug molnupiravir for restricted use in emergency situations.

Earlier this year, the Sun Pharma had signed a non-exclusive voluntary licensing agreement with US-based Merck to manufacture and supply a generic version of molnupiravir in over 100 low and middle-income countries (LMICs) including India.

The DCGI, based on the review of clinical data of molnupiravir has approved molnupiravir for treatment of adult patients with Covid-19, with oxygen saturation less than 93 per cent and who have high risk of progression of the disease, including hospitalisation or death.

“Molnupiravir is an important addition to the portfolio of oral therapies available for treating Covid-19 patients. In line with our consistent efforts to accelerate access to new drugs for Covid-19 treatment, we will make Molxvir available to patients at an affordable price,” said Kirti Ganorkar, CEO of India Business, Sun Pharma, in a statement.

Ganorkar added that the company is in the process of launching a toll-free helpline to ensure the availability of Molxvir to doctors and patients across India.

“Our endeavour is to make the product available in a week’s time,” she said.

The recommended dose of the drug is 800 mg twice a day for five days. The duration of treatment of molnupiravir is much shorter compared to other therapies which is a significant advantage as it reduces the pill burden and enhances compliance.

Molnupiravir is an oral anti-viral that inhibits the replication of multiple RNA viruses including SARS-CoV-2. The drug is used for the treatment of non-hospitalised patients with Covid-19 globally.

Molnupiravir has been developed by Merck and Ridgeback Biotherapeutics. The US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA) have granted the pill EUA.
IANS

 

spot_imgspot_img

Related articles

Death of 5 tigers: Two arrested for poisoning big cats in revenge for cow’s killing

Bengaluru, June 28: The Forest and Police authorities have cracked the sensational case involving the death of a...

Meghalaya set to get back five villages from Assam

Border pact with Assam by August 15, says Paul Lyngdoh SHILLONG, June 27: The state government said that five...

Forced to do menial work, 2 HNLC cadres surrender

SHILLONG, June 27: Two cadres of the proscribed Hynniewtrep National Liberation Council (HNLC)— Dibarius Jyrwa (32) and Ridor...

MRSSA more potent than ILP in checking influx, says paul

SHILLONG, June 27: With pressure groups time and again raising the demand for inner line permit in Meghalaya,...